- Home
- EVAX vs CMND Comparison
EVAX vs CMND Comparison
Compare EVAX & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- CMND
- Stock Information
- Founded
- EVAX 2008
- CMND 2017
- Country
- EVAX Denmark
- CMND Canada
- Employees
- EVAX N/A
- CMND N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- CMND Health Care
- Exchange
- EVAX Nasdaq
- CMND Nasdaq
- Market Cap
- EVAX 10.8M
- CMND 4.8M
- IPO Year
- EVAX 2021
- CMND N/A
- Fundamental
- Price
- EVAX $2.37
- CMND $1.10
- Analyst Decision
- EVAX Strong Buy
- CMND
- Analyst Count
- EVAX 2
- CMND 0
- Target Price
- EVAX $10.00
- CMND N/A
- AVG Volume (30 Days)
- EVAX 115.9K
- CMND 2.2M
- Earning Date
- EVAX 08-13-2025
- CMND 06-12-2025
- Dividend Yield
- EVAX N/A
- CMND N/A
- EPS Growth
- EVAX N/A
- CMND N/A
- EPS
- EVAX N/A
- CMND N/A
- Revenue
- EVAX $3,293,000.00
- CMND N/A
- Revenue This Year
- EVAX N/A
- CMND N/A
- Revenue Next Year
- EVAX N/A
- CMND N/A
- P/E Ratio
- EVAX N/A
- CMND N/A
- Revenue Growth
- EVAX 2555.64
- CMND N/A
- 52 Week Low
- EVAX $1.20
- CMND $0.80
- 52 Week High
- EVAX $17.75
- CMND $2.30
- Technical
- Relative Strength Index (RSI)
- EVAX 49.33
- CMND 72.14
- Support Level
- EVAX $2.35
- CMND $0.85
- Resistance Level
- EVAX $2.60
- CMND $0.91
- Average True Range (ATR)
- EVAX 0.27
- CMND 0.08
- MACD
- EVAX -0.04
- CMND 0.02
- Stochastic Oscillator
- EVAX 36.36
- CMND 58.82
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.